IgY Antibodies using ANTIBODY PLATFORM Technology

IgY is an immunoglobulin present in egg yolks laid by hens. Rapid production of specific antibodies through well-structured specialized antigen-production technology suggests an infinite challenge to viral diseases, which is easy to mass-produce and can respond quickly to viral diseases that humans have been fighting for all their lives. This is what we call the “Antibody Platform“.

Antigen-Production Technologies

Antibody-Production Technologies

  • Monoclonal antibody
  • Polyclonal antibody

Succeeded in the mass production of Anti-SARS-CoV-2 IgY polyclonal antibody.

  • RBD Antibody
  • NTD Antibody

Succeeded in the production of Anti-SARS-CoV-2 ACE2 monoclonal antibody.

Antibody Platform Developer

CTO of WHONIZ

Prof. Murakami Yasufumi Ph.D. [村上 康文]

Prof. Murakami Yasufumi, founder of OMR and developer of an innovative antibody production platform, will apply a variety of treatment approaches together with WHONIZ to provide new treatment options for cancers that have been difficult to treat (drug resistance, immune-evasion cancer, cancer stem cells, etc.) or refractory autoimmune diseases, neurodegenerative disease, etc., which will be positioned as an important paradigm in the future medical industry.

Profile

  • World’s first success in mass production of SARS-CoV-2 neutralizing antibody, Development of antibody medicine, Establishment of antibody platform
  • Influenza detection antibody 60% market share worldwide, 80% market share in Japan (BMR)


Field of Study

Antibody Medicine/Genome Biology/Genetic Engineering


Career

  • Founded OMR
  • Ph.D., Department of Pharmacy, University of Tokyo (Pharmacy Major)
  • U.S. Alberta Einstein Medical School – Immunology research
  • U.S. Memorial Sloan Kettering Cancer Center – Molecular biology, Virology research
  • Japan RIKEN Institute – Antibody therapeutics, genome biology senior research
  • Professor, Tokyo University of Science, Department of Biological Science and Technology
  • Visiting professor at Tottori University
  • CTO of DD Supply CTO
  • Visiting professor at Wide River Institute of Immunology, Seoul National University
  • CTO of WHONIZ
  • The current professor emeritus at Tokyo University of Science
OMR’s innovative antibody platform technology

OMR(Order-made Medical Research) has established “ LIMAXYS ™ “, an innovative antibody generating technology using metastatic cancer cell properties and made it possible to generate prominent antibodies against multi-transmembrane target molecules that have been difficult to create. This makes it possible to generate approximately 5,600 antibodies for all of membrane proteins theoretically. Furthermore, OMR is working on to establish “ INTAB ™ ” internalization antibodies technologies targeting intracellular molecules, and ” MUTAB ™ ” selective antibody technologies recognizing disease specific immunogenicity changes associated with genetic mutations,  post-translational modifications and others.

Antibody Engineering


Innovative antibody generating technology using metastatic cancer cell properties. Immunization by target molecule expressed metastatic tumor cell (genetically modified) transplantation.

Bioinformatics


Immunization through epitope prediction via amino acid sequence and 3D structure.

Immuno-Genomics


Immunization with disease specific immunogenicity changes associated with genetic mutations, post-translational modifications and others.

Overview of monoclonal and polyclonal antibodies

Monoclonal antibody

One type of antibody with the same recognized epitope or properties

  • High homogeneity
  • It is possible to mass-produce antibodies with the same properties.
Polyclonal antibody

A gathering of multiple types of antibodies that recognize different epitopes

  • Low manufacturing cost
  • It binds to both antigens and mutant antigens.
Antigen_2

Production of monoclonal and polyclonal antibodies via
OMR with WHONIZ’s Antibody Platform

Anti-ACE2 monoclonal antibody
Anti-Spike protein egg yolk antibody (IgY)

Suppressive mechanism of OMR and WHONIZ’s
Anti-RBD/NTD IgY and Anti-ACE2 antibody against SARS-CoV-2 Virus

Test of neutralizing antibody IgY against SARS-CoV-2(RBD)

Neutralizing Activity of IgY against the spike proteins from the SARS-CoV-2 variants.

Neutralizing Activity of IgY against the spike proteins (RBD) from the SARS-CoV-2 variants.

IC50 values of IgY antibody in the neutralization assay using Spike RBD from various mutant strain of SARS-CoV-2

Analysis of the inhibitory activity of IgY in the binding of
SARS-CoV-2 Spike protein mutant RBDs to human ACE2 receptors

Neutralizing activity of IgY has been proved that inhibits the binding between SARS-CoV-2 Spike protein mutant RBDs and human ACE2 receptors through the Competitive inhibitory activity test (Cell-based ELISA).

IgY effectively inhibited the binding of SARS-CoV-2 Spike protein mutant RBSs to human ACE2 receptors.

Inhibitory activity of IgY antibody in the binding to the SARS-CoV-2 Spike protein RBDs is verified similarly to that of the mouse-derived monoclonal neutralizing antibody.

IC50 values of DDS_IgY in the Competitive inhibitory activity test (Cell-based ELISA) using SARS-CoV-2 Spike mutant RBDs

Test result on the neutralizing activity of IgY against Omicron strain(RBD/NTD)

Test results of IgY antibody against Omicron mutant strain

Spike proteins for various mutant strains of SARS-CoV-2 have been prepared and subjected to the neutralization assay shown in the previous slide. Two different preparation of purified IgY were tested and both of them exhibited complete inhibition of binding of spike to ACE2 receptor.

IgY Antibodies using ANTIBODY PLATFORM Technology

IgY is an immunoglobulin present in egg yolks laid by hens. Rapid production of specific antibodies through well-structured specialized antigen-production technology suggests an infinite challenge to viral diseases, which is easy to mass-produce and can respond quickly to viral diseases that humans have been fighting for all their lives. This is what we call the “Antibody Platform“.

Antigen-Production Technologies
Antibody-Production Technologies
  • Monoclonal antibody
  • Polyclonal antibody
Succeeded in the mass production of Anti-SARS-CoV-2 IgY polyclonal antibody.
  • RBD Antibody
  • NTD Antibody
Succeeded in the production of Anti-SARS-CoV-2 ACE2 monoclonal antibody.

Antibody Platform Developer
CTO of WHONIZ
Prof. Murakami Yasufumi Ph.D. [村上 康文]

Prof. Murakami Yasufumi, founder of OMR and developer of an innovative antibody production platform, will apply a variety of treatment approaches together with WHONIZ to provide new treatment options for cancers that have been difficult to treat (drug resistance, immune-evasion cancer, cancer stem cells, etc.) or refractory autoimmune diseases, neurodegenerative disease, etc., which will be positioned as an important paradigm in the future medical industry.

Profile
  • World’s first success in mass production of SARS-CoV-2 neutralizing antibody, Development of antibody medicine, Establishment of antibody platform
  • Influenza detection antibody 60% market share worldwide, 80% market share in Japan (BMR)

Field of Study

Antibody Medicine/Genome Biology/Genetic Engineering


Career
  • Founded OMR
  • Ph.D., Department of Pharmacy, University of Tokyo (Pharmacy Major)
  • U.S. Alberta Einstein Medical School – Immunology research
  • U.S. Memorial Sloan Kettering Cancer Center – Molecular biology, Virology research
  • Japan RIKEN Institute – Antibody therapeutics, genome biology senior research
  • Professor, Tokyo University of Science, Department of Biological Science and Technology
  • Visiting professor at Tottori University
  • CTO of DD Supply CTO
  • Visiting professor at Wide River Institute of Immunology, Seoul National University
  • CTO of WHONIZ
  • The current professor emeritus at Tokyo University of Science
OMR’s innovative antibody platform technology

OMR(Order-made Medical Research) has established “ LIMAXYS ™ “, an innovative antibody generating technology using metastatic cancer cell properties and made it possible to generate prominent antibodies against multi-transmembrane target molecules that have been difficult to create. This makes it possible to generate approximately 5,600 antibodies for all of membrane proteins theoretically. Furthermore, OMR is working on to establish “ INTAB ™ ” internalization antibodies technologies targeting intracellular molecules, and ” MUTAB ™ ” selective antibody technologies recognizing disease specific immunogenicity changes associated with genetic mutations,  post-translational modifications and others.

Antibody Engineering


Innovative antibody generating technology using metastatic cancer cell properties. Immunization by target molecule expressed metastatic tumor cell (genetically modified) transplantation.

Bioinformatics


Immunization through epitope prediction via amino acid sequence and 3D structure.

Immuno-Genomics


Immunization with disease specific immunogenicity changes associated with genetic mutations, post-translational modifications and others.

Overview of monoclonal and polyclonal antibodies

Monoclonal antibody
One type of antibody with the same recognized epitope or properties
  • High homogeneity
  • It is possible to mass-produce antibodies with the same properties.
Polyclonal antibody
A gathering of multiple types of antibodies that recognize different epitopes
  • Low manufacturing cost
  • It binds to both antigens and mutant antigens.

Production of monoclonal and polyclonal antibodies viaOMR with WHONIZ’s Antibody Platform

Anti-ACE2 monoclonal antibody
Anti-Spike protein egg yolk antibody (IgY)

Suppressive mechanism of OMR and WHONIZ’sAnti-RBD/NTD IgY and Anti-ACE2 antibody against SARS-CoV-2 Virus

Test of neutralizing antibody IgY against SARS-CoV-2(RBD)

Neutralizing Activity of IgY against the spike proteins from the SARS-CoV-2 variants.

Neutralizing Activity of IgY against the spike proteins (RBD) from the SARS-CoV-2 variants.

IC50 values of IgY antibody in the neutralization assay using Spike RBD from various mutant strain of SARS-CoV-2

Analysis of the inhibitory activity of IgY in the binding of
SARS-CoV-2 Spike protein mutant RBDs to human ACE2 receptors

Neutralizing activity of IgY has been proved that inhibits the binding between SARS-CoV-2 Spike protein mutant RBDs and human ACE2 receptors through the Competitive inhibitory activity test (Cell-based ELISA).

IgY effectively inhibited the binding of SARS-CoV-2 Spike protein mutant RBSs to human ACE2 receptors.

Inhibitory activity of IgY antibody in the binding to the SARS-CoV-2 Spike protein RBDs is verified similarly to that of the mouse-derived monoclonal neutralizing antibody.

IC50 values of DDS_IgY in the Competitive inhibitory activity test (Cell-based ELISA) using SARS-CoV-2 Spike mutant RBDs

Test result on the neutralizing activity of IgY against Omicron strain(RBD/NTD)

Test results of IgY antibody against Omicron mutant strain

Spike proteins for various mutant strains of SARS-CoV-2 have been prepared and subjected to the neutralization assay shown in the previous slide. Two different preparation of purified IgY were tested and both of them exhibited complete inhibition of binding of spike to ACE2 receptor.